The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells

Patients with refractory relapsed multiple myeloma respond to combination treatment with elotuzumab and lenalidomide. The mechanisms underlying this observation are not fully understood. Furthermore, biomarkers predictive of response have not been identified to date. To address these issues, we used...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Kelden, Keam, Simon P., Zhu, Joe Jiang, Meyran, Deborah, D’Souza, Criselle, Macdonald, Sean, Campbell, Kerry, Robbins, Michael, Bezman, Natalie A., Todd, Kirsten, Quach, Hang, Ritchie, David S., Harrison, Simon J., Prince, H. Miles, Trapani, Joseph A., Jenkins, Misty R., Beavis, Paul A., Darcy, Phillip K., Neeson, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Cell Therapy & Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827168/
https://www.ncbi.nlm.nih.gov/pubmed/35770527
http://dx.doi.org/10.3324/haematol.2021.279930

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827168/
https://www.ncbi.nlm.nih.gov/pubmed/35770527
http://dx.doi.org/10.3324/haematol.2021.279930

Ejemplares similares